JacobsonL., GoldwasserE., FriedW.The role of the kidney in erythropoiesis.Nature1957; 179: 633–634.
2.
FisherJ.W.Mechanism of the anemia of chronic renal failure.Nephron.1980; 25: 106–111.
3.
HottaT., MaedaH., SuzukiI.Selective inhibition of erythropoiesis by sera from patients with chronic renal failure.Proc Soc Exp Biol Med.1987; 186: 47–51.
4.
EschbachJ., MladenovicJ., GarciaJ.The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo.J Clin Invest.1984; 74: 434–441.
5.
JacobsK., ShoemakerC., RudersdorfR.Isolation and characterization of genomic and cDNA clones of human erythropoietin (Letter).Nature1985; 313: 806–810.
6.
EgrieJ., StricklandT., LaneJ.Characterization and biological effects of recombinant human erythropoietin.Immunobiology.1986; 172: 213–224.
7.
WinearlsC., OliverD., PippardM.Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis.Lancet.1986; 2: 1175–1178.
8.
ZinsB., DruekeT., ZingraffeJ.Erythropoietin treatment in anaemic patients on hemodialysis (Letter).Lancet.1986; 2: 1329.
9.
EschbachJ., EgrieJ., DowningM.R.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.N Engl J Med.1987; 316: 73–78.
10.
BargmanJ., BreborowiczA., RodelaH.Intraperitoneal administration of recombinant human erythropoietin in uremic animals.Perit Dial Int.1988; 8: 249–252.
11.
BoelaertJ., SchurgersM., MatthysE.Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in CAPD patients.Perit Dial Int.1989; 9: 95–98.
12.
MacdougallI., RobertsD., NeubertP.Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.Lancet.1989; 1: 425–427.
